Isomorphic Labs, an AI-first drug design company spun out of Google DeepMind, announced on May 12, 2026 that it had closed a $2.1 billion Series B financing round, marking one of the largest capital raises to date for an applied AI company in the life sciences sector.
Round structure and investors
<cite index="1-4">The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund</cite>. <cite index="6-4">The round was completed at an undisclosed valuation.</cite> According to secondary reporting, <cite index="7-4">the round brings the company's total funding to approximately $2.6 billion</cite>, following a <cite index="6-9">2025 Series A of $600 million that was likewise steered by Thrive Capital</cite>. CEO Demis Hassabis told Bloomberg that <cite index="6-10,6-11">returning to a familiar backer rather than courting new ones was a deliberate choice, citing the time and discretion required in his line of work: "We didn't want to spend months road-showing"</cite>.
Use of proceeds
<cite index="1-5">The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic.</cite> <cite index="6-5,6-6">The company said the capital will go toward continued development of IsoDDE, as well as hiring across its sites in London, Cambridge, Massachusetts, and Lausanne, Switzerland. Hassabis said the funding will also help expand the company's headcount from over 350 people, according to Bloomberg.</cite>
Technology and platform
Isomorphic Labs was <cite index="6-7">founded in 2021 as a spinout from Google DeepMind, Alphabet's AI research lab, with a focus on commercializing the AlphaFold protein-structure prediction model</cite>. <cite index="1-16">The company has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities.</cite> <cite index="7-9">The stated goal is to predict not just what a protein looks like but also how it will behave when introduced to a specific synthetic compound, at a level of precision and speed that traditional lab-based "trial and error" cannot match.</cite>
In a statement accompanying the announcement, Hassabis framed the round as a transition from research to deployment: <cite index="1-11,1-12">"Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."</cite>
Pharmaceutical partnerships
<cite index="1-19">Isomorphic Labs maintains a portfolio of strategic partnerships with industry leaders including Novartis, Eli Lilly, and Johnson & Johnson.</cite> Company president Max Jaderberg said that <cite index="1-13,1-14">the milestone is built on the strength of the AI drug design engine, which has already proven its worth across internal programs by hitting key milestones and identifying viable candidates, providing a repeatable way to design new medicines for a wide range of diseases</cite>.
Corporate trajectory
The addition of sovereign capital from MGX (United Arab Emirates), Temasek (Singapore), and the UK Sovereign AI Fund signals an internationalization of Isomorphic's investor base beyond Alphabet's orbit. <cite index="6-12,6-13">A full separation from Alphabet at some point down the road has not been ruled out, Hassabis indicated to Bloomberg: "That's definitely one of the options," he said.</cite> No human patient has yet been dosed with an Isomorphic-designed candidate, leaving clinical validation as the next critical milestone for the platform.